DEVELOPMENT OF ANTIVIRAL AGENTS AGAINST HIV1

全世界都在努力开发有效的抗病毒策略 抗HIV-1的抗体，用于预防和干预人类艾滋病 疫情我们使用了两种方法来开发HIV-1抗病毒药物： 重组反义质粒DNA可以转录反义RNA， 抑制HIV-1复制;和质粒DNA疫苗，其可以潜在地 产生免疫反应以防止HIV-1感染。体外研究 表明重组反义质粒DNA对HIV-1有抑制作用 复制选择的嗜T细胞和嗜巨噬细胞分离株， 代表了北美出现的病毒谱。电流 正在努力开发一种有效的包装细胞系统， 体内递送。对HIV-1疫苗DNA的研究表明， gag和env基因的构建和发展， 体液和细胞免疫反应。安全评价 两种抗病毒构建体也将进行评估， 使用这些新方法的人类风险。 世界范围内正在进行主要的研究工作，以开发抗病毒药物 抗HIV-1的抗体，用于预防和干预人类艾滋病 疫情反义DNA和质粒DNA疫苗领域是新颖的 并作为潜在的治疗方法和疫苗 艾滋病毒-1的战略。我们在这些领域的实验室研究为 我们积极提供相关产品的指导和专家评审 提交给FDA进行评估。

There is a world-wide effort to develop effective anti-viral strategies against HIV-1 for the prevention and intervention of the human AIDS epidemic. We have used two approaches to develop HIV-1 antivirals: a recombinant antisense plasmid DNA that can transcribe antisense RNAs to inhibit HIV-1 replication; and a plasmid DNA vaccine which can potentially generate immune responses to prevent HIV-1 infection. In vitro studies indicate that the recombinant antisense plasmid DNA can inhibit HIV-1 replication of selected T-cell-tropic and macrophage-tropic isolates that represent the spectrum of viruses occurring in North America. Current efforts are underway to develop an efficient packaging cell system for delivery in vivo. Studies of the HIV-1 vaccine DNAs indicate expression of the gag and env genes present in the construct and development of humoral and cellular immune responses in monkeys. Safety assessment of both antiviral constructs will be also be conducted to evaluate potential human risk using these novel approaches. Major research efforts are underway worldwide to develop antiviral agents against HIV-1 for the prevention and intervention of the human AIDS epidemic. The areas of antisense DNAs and plasmid DNA vaccines are novel and rigorously being pursued as potential therapeutics and vaccine strategies against HIV-1. Our laboratory research in these areas prepare us to actively provide guidance and expert review in related products submitted to the FDA for evaluation.